

Patient Name: 김삼식
Gender: Male
Sample ID: N26-52

Primary Tumor Site: Bile duct
Collection Date: 2025.03.25

Sample Cancer Type: Cholangiocarcinoma

Table of Contents	Page	Report Highlights
Variant Details	1	0 Relevant Biomarkers
Biomarker Descriptions	2	0 Therapies Available
		0 Clinical Trials

Relevant Cholangiocarcinoma Findings

Gene	Finding	Gene	Finding
BRAF	None detected	NTRK1	None detected
ERBB2	None detected	NTRK2	None detected
FGFR2	None detected	NTRK3	None detected
IDH1	None detected	RET	None detected
KRAS	None detected		

Genomic Alteration	Finding
Tumor Mutational Burden	1.89 Mut/Mb measured

Relevant Biomarkers

No biomarkers associated with relevant evidence found in this sample

Prevalent cancer biomarkers without relevant evidence based on included data sources

Microsatellite stable, Tumor Mutational Burden

Variant Details

DNA Sequence Variants							
Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect
TET2	p.(P23T)	c.67C>A	.	chr4:106155166	45.94%	NM_001127208.3	missense
MSH3	p.(A61_P63dup)	c.189_190insGCAGCG CCC	.	chr5:79950735	35.98%	NM_002439.5	nonframeshift Insertion

Biomarker Descriptions

Microsatellite stable

Background: Microsatellites are short tandem repeats (STR) of 1 to 6 bases of DNA between 5 to 50 repeat units in length. There are approximately 0.5 million STRs that occupy 3% of the human genome¹. Microsatellite instability (MSI) is defined as a change in the length of a microsatellite in a tumor as compared to normal tissue^{2,3}. MSI is closely tied to the status of the mismatch repair (MMR) genes. In humans, the core MMR genes include MLH1, MSH2, MSH6, and PMS2⁴. Mutations and loss of expression in MMR genes, known as defective MMR (dMMR), lead to MSI. In contrast, when MMR genes lack alterations, they are referred to as MMR proficient (pMMR). Consensus criteria were first described in 1998 and defined MSI-high (MSI-H) as instability in two or more of the following five markers: BAT25, BAT26, D5S346, D2S123, and D17S250⁵. Tumors with instability in one of the five markers were defined as MSI-low (MSI-L) whereas, those with instability in zero markers were defined as MS-stable (MSS)⁵. Tumors classified as MSI-L are often phenotypically indistinguishable from MSS tumors and tend to be grouped with MSS^{6,7,8,9,10}. MSI-H is a hallmark of Lynch syndrome (LS), also known as hereditary non-polyposis colorectal cancer, which is caused by germline mutations in the MMR genes³. LS is associated with an increased risk of developing colorectal cancer, as well as other cancers, including endometrial and stomach cancer^{2,3,7,11}.

Alterations and prevalence: The MSI-H phenotype is observed in 30% of uterine corpus endothelial carcinoma, 20% of stomach adenocarcinoma, 15-20% of colon adenocarcinoma, and 5-10% of rectal adenocarcinoma^{2,3,12,13}. MSI-H is also observed in 5% of adrenal cortical carcinoma and at lower frequencies in other cancers such as esophageal, liver, and ovarian cancers^{12,13}.

Potential relevance: Anti-PD-1 immune checkpoint inhibitors including pembrolizumab¹⁴ (2014) and nivolumab¹⁵ (2015) are approved for patients with MSI-H or dMMR colorectal cancer who have progressed following chemotherapy. Pembrolizumab¹⁴ is also approved as a single agent, for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR with disease progression on prior therapy who are not candidates for surgery or radiation. Importantly, pembrolizumab is approved for the treatment of MSI-H or dMMR solid tumors that have progressed following treatment, with no alternative option and is the first anti-PD-1 inhibitor to be approved with a tumor agnostic indication¹⁴. Dostarlimab¹⁶ (2021) is also approved for dMMR recurrent or advanced endometrial carcinoma or solid tumors that have progressed on prior treatment and is recommended as a subsequent therapy option in dMMR/MSI-H advanced or metastatic colon or rectal cancer^{8,17}. The cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody, ipilimumab¹⁸ (2011), is approved alone or in combination with nivolumab in MSI-H or dMMR colorectal cancer that has progressed following treatment with chemotherapy. MSI-H may confer a favorable prognosis in colorectal cancer although outcomes vary depending on stage and tumor location^{8,19,20}. Specifically, MSI-H is a strong prognostic indicator of better overall survival (OS) and relapse free survival (RFS) in stage II as compared to stage III colorectal cancer patients²⁰. The majority of patients with tumors classified as either MSS or pMMR do not benefit from treatment with single-agent immune checkpoint inhibitors as compared to those with MSI-H tumors^{21,22}. However, checkpoint blockade with the addition of chemotherapy or targeted therapies have demonstrated response in MSS or pMMR cancers^{21,22}.

Genes Assayed

Genes Assayed for the Detection of DNA Sequence Variants

ABL1, ABL2, ACVR1, AKT1, AKT2, AKT3, ALK, AR, ARAF, ATP1A1, AURKA, AURKB, AURKC, AXL, BCL2, BCL2L12, BCL6, BCR, BMP5, BRAF, BTK, CACNA1D, CARD11, CBL, CCND1, CCND2, CCND3, CCNE1, CD79B, CDK4, CDK6, CHD4, CSF1R, CTNNA1, CUL1, CYSLTR2, DDR2, DGCR8, DROSHA, E2F1, EGFR, EIF1AX, EPAS1, ERBB2, ERBB3, ERBB4, ESR1, EZH2, FAM135B, FGF7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FLT4, FOXA1, FOXL2, FOXO1, GATA2, GLI1, GNA11, GNAQ, GNAS, HIF1A, HRAS, IDH1, IDH2, IKBKB, IL6ST, IL7R, IRF4, IRS4, KCNJ5, KDR, KIT, KLF4, KLF5, KNSTRN, KRAS, MAGOH, MAP2K1, MAP2K2, MAPK1, MAX, MDM4, MECOM, MED12, MEF2B, MET, MITF, MPL, MTOR, MYC, MYCN, MYD88, MYO10, NFE2L2, NRAS, NSD2, NT5C2, NTRK1, NTRK2, NTRK3, NUP93, PAX5, PCBP1, PDGFRA, PDGFRB, PIK3C2B, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R2, PIM1, PLAG1, PPP2R1A, PPP6C, PRKACA, PTPN11, PTPRD, PXDNL, RAC1, RAF1, RARA, RET, RGS7, RHEB, RHOA, RICTOR, RIT1, ROS1, RPL10, SETBP1, SF3B1, SIX1, SIX2, SLCO1B3, SMC1A, SMO, SNCAIP, SOS1, SOX2, SPOP, SRC, SRSF2, STAT3, STAT5B, STAT6, TAF1, TERT, TGFB1, TOP1, TOP2A, TPMT, TRRAP, TSHR, U2AF1, USP8, WAS, XPO1, ZNF217, ZNF429

Genes Assayed for the Detection of Copy Number Variations

ABC1, ABL1, ABL2, ABRAXAS1, ACVR1B, ACVR2A, ADAMTS12, ADAMTS2, AKT1, AKT2, AKT3, ALK, AMER1, APC, AR, ARAF, ARHGAP35, ARID1A, ARID1B, ARID2, ARID5B, ASXL1, ASXL2, ATM, ATR, ATRX, AURKA, AURKB, AXIN1, AXIN2, AXL, B2M, BAP1, BARD1, BCL2, BCL2L12, BCL6, BCOR, BLM, BMP2, BRAF, BRCA1, BRCA2, BRIP1, CARD11, CASP8, CBF, CBL, CCND1, CCND2, CCND3, CCNE1, CD274, CD276, CDC73, CDH1, CDH10, CDK12, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CHD4, CHEK1, CHEK2, CIC, CREBBP, CSMD3, CTCF, CTLA4, CTNND2, CUL3, CUL4A, CUL4B, CYLD, CYP2C9, DAXX, DDR1, DDR2, DDX3X, DICER1, DNMT3A, DOCK3,

Genes Assayed (continued)

Genes Assayed for the Detection of Copy Number Variations (continued)

DPYD, DSC1, DSC3, EGFR, EIF1AX, ELF3, EMSY, ENO1, EP300, EPCAM, EPHA2, ERAP1, ERAP2, ERBB2, ERBB3, ERBB4, ERCC2, ERCC4, ERRF1, ESR1, ETV6, EZH2, FAM135B, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FAT1, FBXW7, FGF19, FGF23, FGF3, FGF4, FGF9, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FLT4, FOXA1, FUBP1, FYN, GATA2, GATA3, GLI3, GNA13, GNAS, GPS2, HDAC2, HDAC9, HLA-A, HLA-B, HNF1A, IDH2, IGF1R, IKBKB, IL7R, INPP4B, JAK1, JAK2, JAK3, KDM5C, KDM6A, KDR, KEAP1, KIT, KLF5, KMT2A, KMT2B, KMT2C, KMT2D, KRAS, LARP4B, LATS1, LATS2, MAGOH, MAP2K1, MAP2K4, MAP2K7, MAP3K1, MAP3K4, MAPK1, MAPK8, MAX, MCL1, MDM2, MDM4, MECOM, MEF2B, MEN1, MET, MGA, MITF, MLH1, MLH3, MPL, MRE11, MSH2, MSH3, MSH6, MTAP, MTOR, MUTYH, MYC, MYCL, MYCN, MYD88, NBN, NCOR1, NF1, NF2, NFE2L2, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NRAS, NTRK1, NTRK3, PALB2, PARP1, PARP2, PARP3, PARP4, PBRM1, PCBP1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PDIA3, PGD, PHF6, PIK3C2B, PIK3CA, PIK3CB, PIK3R1, PIK3R2, PIM1, PLAG1, PMS1, PMS2, POLD1, POLE, POT1, PPM1D, PPP2R1A, PPP2R2A, PPP6C, PRDM1, PRDM9, PRKACA, PRKAR1A, PTCH1, PTEN, PTPN11, PTPRT, PXDNL, RAC1, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAF1, RARA, RASA1, RASA2, RB1, RBM10, RECQL4, RET, RHEB, RICTOR, RIT1, RNASEH2A, RNASEH2B, RNF43, ROS1, RPA1, RPS6KB1, RPTOR, RUNX1, SDHA, SDHB, SDHD, SETBP1, SETD2, SF3B1, SLCO1B3, SLX4, SMAD2, SMAD4, SMARCA4, SMARCB1, SMC1A, SMO, SOX9, SPEN, SPOP, SRC, STAG2, STAT3, STAT6, STK11, SUFU, TAP1, TAP2, TBX3, TCF7L2, TERT, TET2, TGFBR2, TNFAIP3, TNFRSF14, TOP1, TP53, TP63, TPMT, TPP2, TSC1, TSC2, U2AF1, USP8, USP9X, VHL, WT1, XPO1, XRCC2, XRCC3, YAP1, YES1, ZFH3, ZMYM3, ZNF217, ZNF429, ZRSR2

Genes Assayed for the Detection of Fusions

AKT2, ALK, AR, AXL, BRAF, BRCA1, BRCA2, CDKN2A, EGFR, ERBB2, ERBB4, ERG, ESR1, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, FGR, FLT3, JAK2, KRAS, MDM4, MET, MYB, MYBL1, NF1, NOTCH1, NOTCH4, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PDGFRB, PIK3CA, PPARG, PRKACA, PRKACB, PTEN, RAD51B, RAF1, RB1, RELA, RET, ROS1, RSPO2, RSPO3, TERT

Genes Assayed with Full Exon Coverage

ABRAXAS1, ACVR1B, ACVR2A, ADAMTS12, ADAMTS2, AMER1, APC, ARHGAP35, ARID1A, ARID1B, ARID2, ARID5B, ASXL1, ASXL2, ATM, ATR, ATRX, AXIN1, AXIN2, B2M, BAP1, BARD1, BCOR, BLM, BMPR2, BRCA1, BRCA2, BRIP1, CALR, CASP8, CBF3, CD274, CD276, CDC73, CDH1, CDH10, CDK12, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CHEK1, CHEK2, CIC, CIITA, CREBBP, CSMD3, CTCF, CTLA4, CUL3, CUL4A, CUL4B, CYLD, CYP2C9, CYP2D6, DAXX, DDX3X, DICER1, DNMT3A, DOCK3, DPYD, DSC1, DSC3, ELF3, ENO1, EP300, EPCAM, EPHA2, ERAP1, ERAP2, ERCC2, ERCC4, ERCC5, ERRF1, ETV6, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FAS, FAT1, FBXW7, FUBP1, GATA3, GNA13, GPS2, HDAC2, HDAC9, HLA-A, HLA-B, HNF1A, ID3, INPP4B, JAK1, JAK2, JAK3, KDM5C, KDM6A, KEAP1, KLHL13, KMT2A, KMT2B, KMT2C, KMT2D, LARP4B, LATS1, LATS2, MAP2K4, MAP2K7, MAP3K1, MAP3K4, MAPK8, MEN1, MGA, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MTAP, MTUS2, MUTYH, NBN, NCOR1, NF1, NF2, NOTCH1, NOTCH2, NOTCH3, NOTCH4, PALB2, PARP1, PARP2, PARP3, PARP4, PBRM1, PDCD1, PDCD1LG2, PDIA3, PGD, PHF6, PIK3R1, PMS1, PMS2, POLD1, POLE, POT1, PPM1D, PPP2R2A, PRDM1, PRDM9, PRKAR1A, PSMB10, PSMB8, PSMB9, PTCH1, PTEN, PTPRT, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RASA1, RASA2, RB1, RBM10, RECQL4, RNASEH2A, RNASEH2B, RNASEH2C, RNF43, RPA1, RPL22, RPL5, RUNX1, RUNX1T1, SDHA, SDHB, SDHC, SDHD, SETD2, SLX4, SMAD2, SMAD4, SMARCA4, SMARCB1, SOCS1, SOX9, SPEN, STAG2, STAT1, STK11, SUFU, TAP1, TAP2, TBX3, TCF7L2, TET2, TGFBR2, TMEM132D, TNFAIP3, TNFRSF14, TP53, TP63, TPP2, TSC1, TSC2, UGT1A1, USP9X, VHL, WT1, XRCC2, XRCC3, ZBTB20, ZFH3, ZMYM3, ZRSR2

HRR Details

Gene/Genomic Alteration	Finding
LOH percentage	0.0%
Not Detected	Not Applicable

Homologous recombination repair (HRR) genes were defined from published evidence in relevant therapies, clinical guidelines, as well as clinical trials, and include - BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L.

Thermo Fisher Scientific's Ion Torrent OncoPrint Reporter software was used in generation of this report. Software was developed and designed internally by Thermo Fisher Scientific. The analysis was based on OncoPrint Reporter (6.2.4 data version 2025.12(007)). The data presented here are from a curated knowledge base of publicly available information, but may not be exhaustive. FDA information was sourced from www.fda.gov and is current as of 2025-11-25. NCCN information was sourced from www.nccn.org and is current as of 2025-11-03. EMA information was sourced from www.ema.europa.eu and is current as of 2025-11-25. ESMO information was sourced from www.esmo.org and is current as of 2025-11-03. Clinical Trials information is current as of 2025-11-03. For the most up-to-date information regarding a particular trial, search www.clinicaltrials.gov by NCT ID or search local clinical trials authority website by local identifier listed in 'Other identifiers.' Variants are reported according to HGVS nomenclature and classified following AMP/ASCO/CAP guidelines (Li et al. 2017). Based on the data sources selected, variants, therapies, and trials listed in this report are listed in order of potential clinical significance but not for predicted efficacy of the therapies.

References

1. Lander et al. Initial sequencing and analysis of the human genome. *Nature*. 2001 Feb 15;409(6822):860-921. PMID: 11237011
2. Baudrin et al. Molecular and Computational Methods for the Detection of Microsatellite Instability in Cancer. *Front Oncol*. 2018 Dec 12;8:621. doi: 10.3389/fonc.2018.00621. eCollection 2018. PMID: 30631754
3. Nojadeh et al. Microsatellite instability in colorectal cancer. *EXCLI J*. 2018;17:159-168. PMID: 29743854
4. Saeed et al. Microsatellites in Pursuit of Microbial Genome Evolution. *Front Microbiol*. 2016 Jan 5;6:1462. doi: 10.3389/fmicb.2015.01462. eCollection 2015. PMID: 26779133
5. Boland et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res*. 1998 Nov 15;58(22):5248-57. PMID: 9823339
6. Halford et al. Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. *Cancer Res*. 2002 Jan 1;62(1):53-7. PMID: 11782358
7. Imai et al. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. *Carcinogenesis*. 2008 Apr;29(4):673-80. PMID: 17942460
8. NCCN Guidelines® - NCCN-Colon Cancer [Version 5.2025]
9. Pawlik et al. Colorectal carcinogenesis: MSI-H versus MSI-L. *Dis. Markers*. 2004;20(4-5):199-206. PMID: 15528785
10. Lee et al. Low-Level Microsatellite Instability as a Potential Prognostic Factor in Sporadic Colorectal Cancer. *Medicine (Baltimore)*. 2015 Dec;94(50):e2260. PMID: 26683947
11. Latham et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. *J. Clin. Oncol*. 2019 Feb 1;37(4):286-295. PMID: 30376427
12. Cortes-Ciriano et al. A molecular portrait of microsatellite instability across multiple cancers. *Nat Commun*. 2017 Jun 6;8:15180. doi: 10.1038/ncomms15180. PMID: 28585546
13. Bonneville et al. Landscape of Microsatellite Instability Across 39 Cancer Types. *JCO Precis Oncol*. 2017;2017. PMID: 29850653
14. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf
15. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s131lbl.pdf
16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s009lbl.pdf
17. NCCN Guidelines® - NCCN-Rectal Cancer [Version 4.2025]
18. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s136lbl.pdf
19. Ribic et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. *N. Engl. J. Med*. 2003 Jul 17;349(3):247-57. PMID: 12867608
20. Klingbiel et al. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. *Ann. Oncol*. 2015 Jan;26(1):126-32. PMID: 25361982
21. Hermel et al. The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer. *J Pers Med*. 2019 Jan 16;9(1). PMID: 30654522
22. Ciardiello et al. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. *Cancer Treat. Rev*. 2019 Jun;76:22-32. PMID: 31079031